Although the presence of PD1+ CD8+ T-cells was not changed, ceralasertib treatment induced a substantial increase in the expression of PD1 in the total population of tumor CD4+ T-cells as well as CD4+ CD44lo/- CD62L+ T effector cells. The gene discussed is SELL; the disease is neoplasm.